Cvs (CVS) Stock
Retail pharmacy giant with insurance and care services. Here's the price, business snapshot, and what's worth knowing about Cvs in September 2026.
CVS Health Corporation is a large integrated healthcare company combining retail pharmacies, pharmacy benefit management (Caremark), and a health insurance arm following its acquisition of Aetna. With a market capitalisation around $105.3bn, CVS aims to offer end-to-end care solutions — from prescriptions and in-store clinical services (MinuteClinic) to care management and insurance products. Investors should note the company’s diversified revenue streams and potential cost synergies from vertical integration, but also be aware of material regulatory, reimbursement and competitive risks. Profitability depends on drug pricing dynamics, insurance margins, and effective cost control across vast retail and clinical operations. The business carries a significant debt load from past acquisitions, so interest-rate sensitivity and cash generation matter. CVS has historically returned cash to shareholders and can be of interest to income and value-oriented investors, though performance can vary and this is general information, not investment advice.
Why It’s Moving
CVS gains traction as investors focus on a cleaner turnaround story and improving earnings momentum.
- CVS highlighted a turnaround across Aetna, pharmacy services and Oak Street Health, signaling that tighter execution is starting to show up in the business mix.
- Management said improved pricing, better operations and heavier use of technology are helping offset still-elevated medical costs, which supports the case for margin recovery.
- The company’s stronger second-quarter results and raised 2026 outlook have kept investor focus on improving earnings momentum, while recent analyst updates have reinforced confidence in the turnaround narrative.
CVS gains traction as investors focus on a cleaner turnaround story and improving earnings momentum.
- CVS highlighted a turnaround across Aetna, pharmacy services and Oak Street Health, signaling that tighter execution is starting to show up in the business mix.
- Management said improved pricing, better operations and heavier use of technology are helping offset still-elevated medical costs, which supports the case for margin recovery.
- The company’s stronger second-quarter results and raised 2026 outlook have kept investor focus on improving earnings momentum, while recent analyst updates have reinforced confidence in the turnaround narrative.
Sixth Month Growth Performance
When is the next earnings date for CVS (CVS)?
CVS Health’s next earnings date is expected to be November 4, 2026. It should cover Q3 2026 results. This timing is consistent with the company’s usual early-November reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying CVS stock, expecting it to rise from its current price of $95.73.
Financial Health
CVS is performing well with strong revenue and cash flow, although profit margins are modest.
Dividend
CVS's dividend yield of 2.78% is reasonable for those seeking income from their investments. If you invested $1000, you would be paid $26.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Integrated care model
Vertical integration across pharmacies, PBM and insurance can create efficiencies and cross-selling opportunities, though benefits depend on successful integration and regulation.
Scale and reach
A large national footprint and broad customer base support stable prescription volumes, but competition from other chains and online players can pressure margins.
Services and tech
Investors may watch digital services, care management and cost controls as potential growth drivers, while remembering that execution and regulatory shifts add uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
